Advertisement

Topics

Latest MRSA (methicillin-resistant Staphylococcus aureus) NewsRSS

00:56 EDT 17th October 2018 | BioPortfolio

AmpliPhi Biosciences Announces Closing of Public Offering

AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the closing of its previously announced underwritten public offering. Gross proceeds to AmpliPhi fro...

Machine-Learning Driven Findings Uncover New Cellular Players in Tumor Microenvironment

NewsThe results identifies the potential involvement of adipocytes in nivolumab (anti-PD1) response in ipilimumab (anti-CTLA4) resistant melanoma patients using a unique machine.

Researchers Produce Virus-resistant Pigs, Could Improve Global Animal Health

NewsResearchers at the University of Missouri have successfully produced a litter of pigs that are genetically resistant to a deadly porcine virus.

New Test Instantly Identifies Antibiotic-Resistant Superbugs

ArticleResearchers from the University of California Berkeley have created a new test that can diagnose patients with antibiotic-resistant strains of bacteria in only a couple of minutes.

Rust Proof Chemical Resistant Island Canopy Hoods

Product AnnouncementHEMCO's Island Canopy Hoods are suitable to locate over peninsulas and are designed to collect and exhaust corrosive vapors, heat, steam and odors.

Treatment Resistant Depression Global Clinical Trials Review, H2, 2018 [Report Updated: 31082018] Prices from USD $2500

Treatment Resistant Depression Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Treatment Resistant Depression Global Clinical Trials Review, H2, 2018" provides an overview of Treatment Resistant Depression clinical trials scenario. This report provides top line data relating to the clinical trials on Treatment Resistant Depression. Report includes an overview of t...

Staphylococcus aureus Infections Global Clinical Trials Review, H2, 2018 [Report Updated: 31082018] Prices from USD $2500

Staphylococcus aureus Infections Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Staphylococcus aureus Infections Global Clinical Trials Review, H2, 2018" provides an overview of Staphylococcus aureus Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Staphylococcus aureus Infections. Report includes an overv...

Promising Agents Could Alter the Treatment Paradigm in Metastatic TNBC

Since triple-negative breast cancer is resistant to multiple therapies, physicians have little flexibility for treatment options. However, anticipation is building for potential alternatives.

Researchers Hope Deadly MRSA Superbugs Take the Bait

NewsResearchers are testing whether a light-active version of the molecule responsible for transporting oxygen in blood circulation may help people infected with MRSA.

Potential Therapy for Treatment-resistant Hypothyroidism Proves Effective

NewsA new “metal-coordinated” drug-delivery technology potentially could be used to supplement the standard therapy for hypothyroidism.

A physician’s breakthrough against prior authorization

A few weeks ago, I saw a young patient who was suffering from an ear infection. It was his fourth visit in eight weeks, as the infection had proven resistant to an escalating series of antibiotics prescribed so far. It was time to bring out a heavier hitter. I prescribed ciprofloxacin, an antibiotic rarely used […]

Peptilogics Receives Regulatory Approval to Initiate First-in-Human Safety Study for Therapeutic Peptide PLG0206

Therapeutic Development to Address Potential Orphan Indication and Global Pandemic Peptilogics, which develops peptide-based therapeutics with its computational biology platform, announced today that it has been cleared by Australia’s Therapeutics Goods Administration to begin the first in-human Phase 1 study of PLG0206, which is being developed to a...

AmpliPhi Biosciences Announces Pricing of $6.6 Million Underwritten Public Offering

AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the pricing of an underwritten public offering of 16,537,500 shares of its common stock (or pre-fund...

Arkansas farmers defy authorities, spray banned GMO dicamba resistant soybean and cotton

Probiotic Good Bacteria Use Fengycins to Eliminate Bad Bacteria

Infections by pathogenic Staphylococcus aureus bacteria cause many tens of thousands of deaths every year, and the threat of antibiotic-resistant strains, including methicillin-resistant S. aureus (MRSA) is escalating. New research by National Institutes of Health (NIH) scientists now suggests how probiotic Bacillus bacteria can eliminate the reservoir of these potentially harmful bacteria th...

Prevalence of different carbapenemase genes among carbapenem-resistant Acinetobacter baumannii blood isolates in Taiwan

Although the prevalence of the carbapenem-resistant A. baumannii (CRAB) has increased in Taiwan, few studies have elucidated the prevalence of different carbapenemase genes in Taiwan. The first objective of this ...

Probiotic Bacillus Found to Eliminate Staphylococcus Bacteria

NewsNew research shows that a "good" bacterium found in probiotic digestive supplements helps eliminate Staphylococcus aureus.Contributed A

Ketamine may — emphasis on the "may" — ease treatment-resistant depression. But buyer beware: some #ketamine clinics make sweeping claims that aren't backed by evidence. https://buff.ly/2C0MMxH pic.twitter.com/7HwY1bOWbY

Ketamine may — emphasis on the "may" — ease treatment-resistant depression. But buyer beware: some #ketamine clinics make sweeping claims that aren't backed by evidence. https://buff.ly/2C0MMxH  pic.twitter.com/7HwY1bOWbY

Researcher Work to Create Bacteria-Resistant Polymers

ArticleResearchers have developed a new approach to fighting the growing drug-resistant bacteria problem.Staff Author: 

Major London Hospital uses ProtoCOL 3 Automated Colony Counter to Rapidly and Accurately Track Spread of Antibiotic Resistant Superbugs

Synbiosis, a long-established, expert manufacturer of automatedmicrobiological systems, is pleased to announce its ProtoCOL 3 automated colony counter is being used at a major teaching hospital in London to accurately track the spread of Carbapenem-Resistant bacteria (CRB) superbugs. Microbiologists in the infection control group at the hospital are using ProtoCOL 3 to count colonies of Carbapenem...

AmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference

13 patients with serious and life-threatening S. aureus infections were treated with AB-SA01 at the Westmead Hospital in Sydney under AmpliPhi’s expanded access program Patients suffered from severe S. aureus bacteremia and sepsis, including infective endocarditis and prosthetic valve endocarditis 83% (10 out ...

Prevalence of methicillin resistant Staphylococcus aureus, multidrug resistant and extended spectrum β-lactamase producing gram negative bacilli causing wound infections at a tertiary care hospital of Nepal

Treatment and prevention of wound infection continues to be a challenging issue in clinical settings of Nepal especially in the context of globally growing problem of antimicrobial resistance. Study on opportu...

MicuRx Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 24072018] Prices from USD $250

SummaryMicuRx Pharmaceuticals Inc MicuRx is a developer of antibiotics for drugresistant bacterial infections. The company develops a pipeline of antimicrobial agents using its proprietary drug discovery platform to treat both grampositive and gramnegative bacterial infections. It offers product candidates which include MRXI, an oxazolidinone antibiotic, which is intended for the treatment of meth...

C5a Anaphylatoxin Chemotactic Receptor 1 CD88 or C5AR1 Pipeline Review, H2 2018 [Report Updated: 14082018] Prices from USD $3500

C5a Anaphylatoxin Chemotactic Receptor 1 CD88 or C5AR1 Pipeline Review, H2 2018SummaryC5a Anaphylatoxin Chemotactic Receptor 1 CD88 or C5AR1 Complement component 5a receptor 1 C5AR1 or CD88 is a G proteincoupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production....

Helix BioMedix Inc Strategic SWOT Analysis Review [Report Updated: 25072018] Prices from USD $125

Helix BioMedix Inc Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.This uptotheminute company report will help you to formulate strategies to drive your business ...

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy MRSA (methicillin-resistant Staphylococcus aureus) market research data and corporate reports here